Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

AIM ImmunoTech Inc. (AIM)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
0.7810+0.0010 (+0.13%)
At close: 04:00PM EDT
0.7720 -0.01 (-1.15%)
After hours: 07:43PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.7800
Open0.7700
Bid0.7810 x 1300
Ask0.8100 x 1300
Day's Range0.7707 - 0.8000
52 Week Range0.5500 - 2.2000
Volume41,143
Avg. Volume513,261
Market Cap37.37M
Beta (5Y Monthly)-0.63
PE Ratio (TTM)N/A
EPS (TTM)-0.3780
Earnings DateMar 29, 2022 - Apr 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.83
  • GlobeNewswire

    AIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and Testing

    Company enters into a lease agreement with the state-supported New Jersey Bioscience Center at North Brunswick, one of the nation’s leading business incubators dedicated to life sciences and biotechnology New Jersey Bioscience Center, NJ New Jersey Bioscience Center,, NJ OCALA, Fla., June 21, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancer

  • GlobeNewswire

    AIM ImmunoTech Bolsters Intellectual Property Portfolio for Ampligen® with Issuance of New Netherlands Utility Patent Covering Ampligen® and other AIM Developed dsRNA Products for Use in COVID-19 Treatment or Prevention

    Further expansion of patent portfolio supports of the Company’s extensive Ampligen research program across multiple types of cancers and viral diseases, including COVID-19 in the NetherlandsOCALA, Fla., June 13, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by

  • GlobeNewswire

    AIM ImmunoTech to Present at the H.C. Wainwright Global Investment Conference

    OCALA, Fla., May 19, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that Thomas K. Equels, M.S. J.D., Chief Executive Officer of AIM, will present at the H.C. Wainwright Global Investment Conference being held May 23-26,

Advertisement
Advertisement